how many people in the us are taking glp 1 According to poll, the share of U.S. adults currently GLP-1 medications for weight loss has climbed to 11% 2026, up from 3% just two years ago. 🔗⬇️ 1 in 10 Americans Has

Expert Panel Recommendations to Reduce GI Side Effects of GLP-1 Recommendations from an expert panel of healthcare providers for patients being treated with GLP-1 medications strongly support the common methodologies of the Pritikin Program as best practice to mitigate and prevent common adverse gastrointestinal side effect, such as vomiting, nausea, diarrhea and constipation

Recent research has revolutionized how we approach colonoscopy preparation, making it more effective and tolerable than ever before

Summary: Current evidence does not establish a definitive causal relationship between weight loss injections (GLP-1 receptor agonists) and pancreatitis, though UK regulatory guidance lists pancreatitis as a potential adverse effect requiring monitoring

This should be discussed as nutrient support, not as a claim that injections address liver conditions